Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Total Valuation
Revolution Medicines has a market cap or net worth of $18.80B. The enterprise value is $18.57B.
Market Cap$18.80B
Enterprise Value$18.57B
Share Statistics
Revolution Medicines has 198,173,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding198,173,400
Owned by Insiders2.25%
Owned by Institutions9.84%
Financial Efficiency
Revolution Medicines’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -56.83%.
Return on Equity (ROE)-0.69
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-56.83%
Return on Capital Employed (ROCE)-0.57
Revenue Per Employee0.00
Profits Per Employee-1.84M
Employee Count616
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Revolution Medicines is ―. Revolution Medicines’s PEG ratio is -0.20.
PE Ratio―
PS Ratio0.00
PB Ratio9.28
Price to Fair Value9.28
Price to FCF-16.57
Price to Operating Cash Flow-20.09
PEG Ratio-0.20
Income Statement
In the last 12 months, Revolution Medicines had revenue of 0.00 and earned -1.13B in profits. Earnings per share was -5.95.
Revenue0.00
Gross Profit-16.56M
Operating Income-1.18B
Pretax Income-1.13B
Net Income-1.13B
EBITDA-1.09B
Earnings Per Share (EPS)-5.95
Cash Flow
In the last 12 months, operating cash flow was -897.74M and capital expenditures -15.99M, giving a free cash flow of -913.73M billion.
Operating Cash Flow-897.74M
Free Cash Flow-913.73M
Free Cash Flow per Share-4.61
Dividends & Yields
Revolution Medicines pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change142.42%
50-Day Moving Average101.72
200-Day Moving Average63.10
Relative Strength Index (RSI)38.84
Average Volume (3m)2.13M
Important Dates
Revolution Medicines upcoming earnings date is May 11, 2026, After Close (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Revolution Medicines as a current ratio of 7.14, with Debt / Equity ratio of 9.73%
Current Ratio7.14
Quick Ratio7.14
Debt to Market Cap0.01
Net Debt to EBITDA0.21
Interest Coverage Ratio-48.80
Taxes
In the past 12 months, Revolution Medicines has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Revolution Medicines EV to EBITDA ratio is -13.68, with an EV/FCF ratio of -16.33.
EV to Sales0.00
EV to EBITDA-13.68
EV to Free Cash Flow-16.33
EV to Operating Cash Flow-16.62
Balance Sheet
Revolution Medicines has $2.03B in cash and marketable securities with $158.70M in debt, giving a net cash position of $1.87B billion.
Cash & Marketable Securities$2.03B
Total Debt$158.70M
Net Cash$1.87B
Net Cash Per Share$9.42
Tangible Book Value Per Share$8.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Revolution Medicines is $141.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$141.67
Price Target Upside49.35% Upside
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast-100.00%
EPS Growth Forecast-44.24%